Intradermal delivery of receptor‐binding domain of SARS‐CoV‐2 spike protein with dissolvable microneedles to induce humoral and cellular responses in mice

The S1 subunit of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) spike protein contains an immunogenic receptor‐binding domain (RBD), which is a promising candidate for the development of a potential vaccine. This study demonstrated that intradermal delivery of an S‐RBD vaccine using a...

Full description

Saved in:
Bibliographic Details
Published in:Bioengineering & Translational Medicine 2021-01, Vol.6 (1), p.e10202-n/a
Main Authors: Kuwentrai, Chaiyaporn, Yu, Jinming, Rong, Li, Zhang, Bao‐Zhong, Hu, Ye‐Fan, Gong, Hua‐Rui, Dou, Ying, Deng, Jian, Huang, Jian‐Dong, Xu, Chenjie
Format: Article
Language:English
Subjects:
Aluminum
Antibodies
Antigens
Binding
Cloning
Coronaviruses
COVID-19
COVID-19 vaccines
Deoxyribonucleic acid
DNA
Domains
Enzymes
Immunization
intradermal delivery
Laboratory animals
microneedle
Molecular weight
Needles
Pandemics
Plasmids
Proteins
Rapid Communication
Receptors
receptor‐binding domain
SARS‐CoV‐2
Severe acute respiratory syndrome coronavirus 2
Skin
spike protein
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The S1 subunit of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) spike protein contains an immunogenic receptor‐binding domain (RBD), which is a promising candidate for the development of a potential vaccine. This study demonstrated that intradermal delivery of an S‐RBD vaccine using a dissolvable microneedle skin patch can induce both significant B‐cell and significant T‐cell responses against S‐RBD. Importantly, the outcomes were comparable to that of conventional bolus injection.
ISSN:2380-6761
2380-6761
DOI:10.1002/btm2.10202